Brief: Karyopharm Announces Completion Of Enrollment In The Phase 3 Sentry Trial In Myelofibrosis
10/09/2025 12:50
Sept 10 (Reuters) - Karyopharm Therapeutics Inc KPTI.O: KARYOPHARM ANNOUNCES COMPLETION OF ENROLLMENT IN THE PHASE 3 SENTRY TRIAL IN MYELOFIBROSIS KARYOPHARM THERAPEUTICS INC - TOP-LINE RESULTS EXPECTED IN FIRST HALF OF 2026 Source text: ID:nPn2NJvLRa Further company coverage: KPTI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview